Skip to main content

Ruff Shamim's Form 4 filing

Reata Pharmaceuticals Inc (RETA) · filed Mar 13, 2023

Accession no.
0001209191-23-018231
Filed
Mar 13, 2023
Trade date
Mar 10, 2023
Filing delay
3 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $480.6K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ruff ShamimCIK 0001685986Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 10, 2023Class A common stockMOption exerciseAcquired+199$27.32+$5,436.685,422Direct
Mar 10, 2023Class A common stockMOption exerciseAcquired+1,326$34.76+$46,091.766,748Direct
Mar 10, 2023Class A common stockMOption exerciseAcquired+4,215$34.76+$146,513.410,963Direct
Mar 10, 2023Class A common stockSSaleDisposed−5,740$83.73−$480,610.25,223Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2023Class A common stockMOption exerciseDisposed−199$0.00$00Direct
Mar 10, 2023Class A common stockMOption exerciseDisposed−1,326$0.00$0443Direct
Mar 10, 2023Class A common stockMOption exerciseDisposed−4,215$0.00$01,405Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)